Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 1;9(2):76-81.
doi: 10.9740/mhc.2019.03.076. eCollection 2019 Mar.

Evaluation of dextromethorphan with select antidepressant therapy for the treatment of depression in the acute care psychiatric setting

Jill L Nofziger  1   2   3 , Chris Paxos  1 , Jessica Emshoff  2 , Chanda Mullen  3
Affiliations

Evaluation of dextromethorphan with select antidepressant therapy for the treatment of depression in the acute care psychiatric setting

Jill L Nofziger et al. Ment Health Clin. .

Abstract

Introduction: Dextromethorphan (DXM), an N-methyl-D-aspartate receptor antagonist, may have ketamine-like antidepressant effects. Dextromethorphan is extensively metabolized via cytochrome P450 (CYP) 2D6, and its half-life in extensive metabolizers is 2 to 4 hours. The purpose of this study was to evaluate the effects of DXM in combination with a moderate-to-strong CYP2D6 inhibitor antidepressant on depression in an acute care psychiatric setting.

Methods: This was a single-center, retrospective chart review of adult patients with a depressive disorder diagnosis. Patients who received select antidepressant therapy with or without scheduled DXM were included. The primary outcome was the difference in time to improvement of depressive symptoms, which was an average composite of physician documentation, nurse documentation, and first time to 24 hours without as-needed anxiolytics or antipsychotics. The study group consisted of patients who received DXM with select antidepressant therapy, whereas the control group included those who received only select antidepressant therapy.

Results: A total of 40 patients were included. The median time to clinical improvement was 3.00 days and 2.83 days for the study group and control group, respectively (P = .986). The incidence of perceptual disturbances and delusions was higher in the study group as compared with the control group (55% and 35% vs 30% and 25%, respectively).

Discussion: Dextromethorphan was not associated with a rapid antidepressant effect. The commonly used dose of 30 mg daily may have been too low to have an effect; additionally, the most frequently utilized select antidepressant, bupropion, has moderately less CYP2D6 inhibition than fluoxetine and paroxetine.

Keywords: CYP2D6 inhibitor; NMDA; bupropion; depression; dextromethorphan; fluoxetine; paroxetine.

PubMed Disclaimer

Conflict of interest statement

Disclosures: The authors have nothing to disclose concerning possible financial or personal relationships with commercial entities that may have a direct or indirect interest in the subject matter of this study.

Figures

FIGURE
FIGURE
Description of study population selection (DXM = dextromethorphan)
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Depression [Internet] World Health Organization. Geneva: World Health Organization. 2018 [updated 2018 Mar 22; cited 2018 Nov 12]Available from: http://www.who.int/mediacentre/factsheets/fs369/en/
    1. American Psychiatric Association (APA) [Internet] Arlington (VA): Practice guideline for the treatment of patients with major depressive disorder. 3rd ed. APA; 2010 [cited 2018 Nov 12]. Available from: http://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/g....
    1. Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR. Dextromethorphan: an update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016;159:1–22. doi: 10.1016/j.pharmthera.2016.01.016. 26826604 DOI: 10.1016/j.pharmthera.2016.01.016 PubMed PMID: PubMed PMID: 26826604. - DOI - PubMed
    1. Nierenberg AA, Fava M, Trivedi MH, Wisniewski SR, Thase ME, McGrath PJ, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D report. Am J Psychiatry. 2006;163(9):1519–30. doi: 10.1176/ajp.2006.163.9.1519. 16946176 quiz 1665. DOI: 10.1176/ajp.2006.163.9.1519 PubMed PMID: PubMed PMID: 16946176. - DOI - PubMed
    1. Zarate CA, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Luckenbaugh DA, et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry. 2006;63(8):856–64. doi: 10.1001/archpsyc.63.8.856. 16894061 DOI: 10.1001/archpsyc.63.8.856 PubMed PMID: PubMed PMID: 16894061. - DOI - PubMed

LinkOut - more resources